These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6678878)

  • 21. Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504).
    Stephens RL; Goodman P; Crawford ED; Spicer CF; Lowe BA; Ahmann FR; Chapman R; Natale RB
    Invest New Drugs; 1990; 8 Suppl 1():S69-71. PubMed ID: 2143177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II trial of iproplatin (CHIP) in previously treated advanced breast cancer.
    Meisner DJ; Ginsberg S; Ditch A; Louie A; Newman N; Comis R; Poiesz B
    Am J Clin Oncol; 1989 Apr; 12(2):129-31. PubMed ID: 2705402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
    Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
    Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
    Gasparini G; Caffo O; Barni S; Frontini L; Testolin A; Guglielmi RB; Ambrosini G
    J Clin Oncol; 1994 Oct; 12(10):2094-101. PubMed ID: 7931479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I-II study on weekly administration of pirarubicin in patients with metastatic breast cancer.
    Dittrich C; Baur M; Mader R; Schlappack O; Dudczak R; Leitha T; Lenzhofer R; Hoffmann S; Vieder L; Heberle U
    Am J Clin Oncol; 1990; 13 Suppl 1():S29-39. PubMed ID: 1963274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer.
    Smith DB; Howell A
    Eur J Cancer Clin Oncol; 1987 Apr; 23(4):391-4. PubMed ID: 3475204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carminomycin. A new anthracycline analog in the treatment of advanced breast cancer.
    Aboud A; Yap HY; Esparza L; Blumenschein GR; Hortobagyi G; Issell B; Bodey GP
    Cancer; 1984 Jan; 53(1):9-12. PubMed ID: 6546298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of carboplatin in patients with ovarian carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.
    Eisenhauer EA; Swenerton KD; Sturgeon JF; Fine S; O'Reilly SE
    Cancer Treat Rep; 1986 Oct; 70(10):1195-8. PubMed ID: 3530446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rubidazone in metastatic breast cancer.
    Legha SS; Benjamin RS; Buzdar AU; Hortobagyi GN; Blumenschein GR
    Cancer Treat Rep; 1979 Jan; 63(1):135-6. PubMed ID: 369685
    [No Abstract]   [Full Text] [Related]  

  • 30. The new anthracycline 4-demethoxydaunorubicin by oral route in advanced pretreated breast cancer and melanoma. A pilot study.
    Martoni A; Pacciarini MA; Pannuti F
    Drugs Exp Clin Res; 1985; 11(2):127-31. PubMed ID: 3915281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II trial of idarubicin in patients with advanced lymphoma.
    Gillies H; Liang R; Rogers H; Harper P; Parapia L; Cox G; Johnson S
    Cancer Chemother Pharmacol; 1988; 21(3):261-4. PubMed ID: 3162850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II trial of gallium nitrate (NSC #15200) in previously treated ovarian carcinoma. A Gynecologic Oncology Group Study.
    Malfetano JH; Blessing JA; Adelson MD
    Am J Clin Oncol; 1991 Aug; 14(4):349-51. PubMed ID: 1862766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II clinical evaluation of doxifluridine.
    Hurteloup P; Armand JP; Cappelaere P; Metz R; Kerbrat P; Keiling R; Fumoleau P; Fargeot P; Schraub S; Bastit P
    Cancer Treat Rep; 1986 Jun; 70(6):731-7. PubMed ID: 2942245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer.
    Ford JM; Panasci L; Leclerc Y; Margolese R
    Cancer Treat Rep; 1987 Oct; 71(10):921-5. PubMed ID: 3308079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity.
    Coleman RE; Maisey MN; Knight RK; Rubens RD
    Eur J Cancer Clin Oncol; 1984 Jun; 20(6):771-6. PubMed ID: 6540179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of oral 4-demethoxydaunorubicin in previously treated (except anthracyclines) metastatic breast cancer patients.
    Kolarić K; Mechl Z; Potrebica V; Sopkova B
    Oncology; 1987; 44(2):82-6. PubMed ID: 3472133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Rubidazone (22 050 RP): clinical study. Phase II trial in solid tumors and lymphomas (author's transl)].
    Chauvergne J; Cappelaere P; Carton M; Gary-Bobo J; Klein T
    Bull Cancer; 1978; 65(1):19-24. PubMed ID: 667371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitoxantrone: a phase II study in the treatment of patients with advanced breast carcinoma and other solid tumours.
    Stuart-Harris RC; Smith IE
    Cancer Chemother Pharmacol; 1982; 8(2):179-82. PubMed ID: 7105382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 4-Demethoxydaunorubicin administered orally in advanced breast cancer. A phase II study.
    De Lena M; Brandi M; Bozzi D; Calabrese P; Romito S
    Tumori; 1988 Feb; 74(1):65-70. PubMed ID: 3162625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of intravenous menogaril in patients with advanced breast cancer.
    Sessa C; Gundersen S; ten Bokkel Huinink W; Renard J; Cavalli F
    J Natl Cancer Inst; 1988 Sep; 80(13):1066-9. PubMed ID: 2970554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.